Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator

Posted on December 11th, 2019 by in Pharma R&D

medicine

When taking a new drug, most patients’ chief concern is whether or not that drug is going to have the intended effect. They aren’t always thinking about what other drugs they might already be taking, and how those drugs could be affected by the new one.

According to the FDA, “Drug-drug interactions occur when two or more drugs react with each other,” which may result in an unexpected side effect. An example that they offer of this is how taking a sedative at the same time as an allergy medication could result in slowing your reactions and making it dangerous to operate a car or machinery.  

Drug-drug interactions, or DDIs, are a serious issue that affect an alarmingly high number of people. While we undoubtedly need to see more comprehensive studies on the problem, those that exist point to DDIs being very prevalent. For instance, this study focused on elderly cancer patients found an average of 2.2 DDIs per patient.

Predictive analytical tools can be a major help in addressing drug-drug interactions and the adverse drug reactions (ADRs) that can result. In fact, just recently, Elsevier announced a collaboration with a number of evaluation partners that include industry leaders – Eli Lilly, Boehringer Ingelheim, Sanofi, Servier and others – to develop a new and improved drug-drug interaction risk calculator (DDIRC).

Elsevier’s PharmaPendium team is working with these pharma companies on a DDIRC capable of analyzing both internal and external data. “By enabling pharmaceutical companies to upload internal data, combined with the high-quality, public FDA/EMA data available in PharmaPendium, the new DDIRC will feature increased predictive power,” stated the press release announcing the collaboration.

The project is a perfect fit for Elsevier, as it gives us the opportunity to leverage our expertise and draw from our high-quality data to take on one of the most pressing issues in the pharmaceutical and healthcare industries. We look forward to further opportunities like this to demonstrate the predictive power of data analytics.

Find out more about another recent industry collaboration, between Elsevier and the FDA, on a drug-induced liver injury (DILI) tool here.

Would you like to learn more about DDI prediction? Get in touch with me at m.wieffer@elsevier.com.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales